Profil Financier
Hasmukh Chudgar & family occupe actuellement le rang #450 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $8.4 B ($0 sur 24h).
Low profile Hasmukh Chudgar founded generics maker Intas Pharmaceuticals in 1977.
Chudgar has long handed over operations to his sons Nimish and Binish, who run the $2.9 billion (revenue) company.
In August 2025, Intas Pharma acquired biosimilar Udenyca from California-based Coherus Life Sciences for $558 million.
The company's portfolio includes an affordable drug to treat breast cancer called Eleftha, which is similar to Roche's Herceptin.
In 2022, the Abu Dhabi Investment Authority bought a 3% stake in Intas from Temasek.
Chudgar's third son Urmish heads the company's biopharma business and is a haematologist-oncologist.
The company's biggest markets are Europe and India.